Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2008 1
2009 2
2010 2
2011 4
2012 3
2015 1
2016 1
2017 1
2018 1
2019 2
2020 3
2021 9
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: coenen m. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Garrelfs SF, et al. N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712. N Engl J Med. 2021. PMID: 33789010 Clinical Trial.
Levels of Alzheimer's disease blood biomarkers are altered after food intake-A pilot intervention study in healthy adults.
Huber H, Ashton NJ, Schieren A, Montoliu-Gaya L, Molfetta GD, Brum WS, Lantero-Rodriguez J, Grötschel L, Stoffel-Wagner B, Coenen M, Weinhold L, Schmid M, Blennow K, Stehle P, Zetterberg H, Simon MC. Huber H, et al. Among authors: coenen m. Alzheimers Dement. 2023 Dec;19(12):5531-5540. doi: 10.1002/alz.13163. Epub 2023 May 27. Alzheimers Dement. 2023. PMID: 37243891
The role of CCR5 in HCV infection.
Coenen M, Nattermann J. Coenen M, et al. Eur J Med Res. 2010 Mar 30;15(3):97-101. doi: 10.1186/2047-783x-15-3-97. Eur J Med Res. 2010. PMID: 20452893 Free PMC article. Review.
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.
Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I, Sellier-Leclerc AL, Lu J, Seddighzadeh A, Habtemariam B, McGregor TL, Fujita KP, Frishberg Y; ILLUMINATE-B Workgroup. Sas DJ, et al. Genet Med. 2022 Mar;24(3):654-662. doi: 10.1016/j.gim.2021.10.024. Epub 2021 Dec 8. Genet Med. 2022. PMID: 34906487 Free article. Clinical Trial.
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P; study collaborators. Frishberg Y, et al. Clin J Am Soc Nephrol. 2021 Jul;16(7):1025-1036. doi: 10.2215/CJN.14730920. Epub 2021 May 13. Clin J Am Soc Nephrol. 2021. PMID: 33985991 Free PMC article. Clinical Trial.
Cardiac resynchronization therapy in chronic heart failure.
Sticherling C, Schaer B, Coenen M, Kühne M, Ammann P, Osswald S. Sticherling C, et al. Among authors: coenen m. Swiss Med Wkly. 2006 Sep 30;136(39-40):611-7. doi: 10.4414/smw.2006.11597. Swiss Med Wkly. 2006. PMID: 17086506 Free article. Review.
Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials.
Breithaupt-Groegler K, Coch C, Coenen M, Donath F, Erb-Zohar K, Francke K, Goehler K, Iovino M, Kammerer KP, Mikus G, Rengelshausen J, Sourgens H, Schinzel R, Sudhop T, Wensing G. Breithaupt-Groegler K, et al. Among authors: coenen m. Eur J Clin Pharmacol. 2017 Apr;73(4):409-416. doi: 10.1007/s00228-016-2189-8. Epub 2017 Jan 7. Eur J Clin Pharmacol. 2017. PMID: 28064353 Free PMC article. Review.
Prevention of cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation: the ODIn-AF trial.
Schrickel JW, Beiert T, Linhart M, Luetkens JA, Schmitz J, Schmid M, Hindricks G, Arentz T, Stellbrink C, Deneke T, Bogossian H, Sause A, Steven D, Gonska BD, Rudic B, Lewalter T, Zabel M, Geisler T, Schumacher B, Jung W, Kleemann T, Luik A, Veltmann C, Coenen M, Nickenig G. Schrickel JW, et al. Among authors: coenen m. Clin Res Cardiol. 2023 Nov 3. doi: 10.1007/s00392-023-02319-9. Online ahead of print. Clin Res Cardiol. 2023. PMID: 37921923
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Böttcher M, Düngen HD, Corcea V, Donath F, Fuhr R, Gal P, Mikus G, Trenk D, Coenen M, Pires PV, Maschke C, Aliprantis AO, Besche N, Becker C. Böttcher M, et al. Among authors: coenen m. Am J Cardiovasc Drugs. 2023 Mar;23(2):145-155. doi: 10.1007/s40256-022-00557-2. Epub 2023 Jan 12. Am J Cardiovasc Drugs. 2023. PMID: 36633816 Free PMC article. Clinical Trial.
39 results